Addendum to the Editorial “Joint Guidance on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors”

TO THE READERSHIP: The purpose of the editorial in the May issue (1) was to bring to the attention of the readership a guidance document written collaboratively by 3 organizations, including the Society of Nuclear Medicine and Molecular Imaging (2). The decision to publish this document in the European Journal of Nuclear Medicine and Molecular Imaging was made collaboratively by the 3 organizations, as was the decision to publish the editorial in The Journal of Nuclear Medicine.

Incidentally, we described clinical trials with these agents that are getting under way in the United States. We overlooked mentioning the availability of 2 ongoing Food and Drug Administration–authorized investigational new drug (IND) trials on high-activity $^{111}$In-octreotide (IND no. 72,037) (3,4) and $^{177}$Lu-octreotate (IND no. 78,256) peptide receptor radionuclide therapies in the United States. These ongoing trials are available at the Excel Diagnostics and Nuclear Oncology Center in Houston, Texas.

REFERENCES


CORRIGENDUM

To the Editor: In the editorial of Delbeke and Graham, the clinical trials were previously stated as IND no. 72,037 (1). The correct IND number is actually 72,038 (3). In addition, the reference to IND no. 78,256 in the editorial was incorrect and should have been 78,256 (3). The correct IND number is actually 78,256 (4).

Dominique Delbeke*
Michael M. Graham

*Vanderbilt University Medical Center
21st Ave. S. and Garland
Nashville, TN 37232

E-mail: dominique.delbeke@vanderbilt.edu

Published online Jun. 3, 2013.
DOI: 10.2967/jnumed.113.126748
Al\textsuperscript{18}F: A New Standard for Radiofluorination

David M. Goldenberg, Robert M. Sharkey, William J. McBride and Otto C. Boerman

Published online: May 17, 2013.
Doi: 10.2967/jnumed.113.125245

This article and updated information are available at:
http://jnm.snmjournals.org/content/54/7/1170.1

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml